Literature DB >> 14555711

Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies.

Robert A Gatenby1, Thomas L Vincent.   

Abstract

Quantitative models from population biology and evolutionary game theory frame the tumor-host interface as a dynamical microenvironment of competing tumor and normal populations. Through this approach, critical parameters that control the outcome of this competition are identified and the conditions necessary for formation of an invasive cancer are defined. Perturbations in these key parameters that destabilize the cancer solution of the state equations and produce tumor regression can be predicted. The mathematical models demonstrate significant theoretical limitations in therapies based solely on cytotoxic drugs. Because these approaches do not alter critical parameters controlling system dynamics, the tumor population growth term will remain positive as long as any individual cells are present so that the tumor will invariably recur unless all proliferative cells are killed. The models demonstrate that such total effectiveness is rendered unlikely by the genotypic heterogeneity of tumor populations (and, therefore, the variability of their response to such drugs) and the ability of tumor cells to adapt to these proliferation constraints by evolving resistant phenotypes. The mathematical models support therapeutic strategies that simultaneously alter several of the key parameters in the state equations. Furthermore, the models demonstrate that administration of cytotoxic therapies will, by reducing the tumor population density, create system dynamics more conducive to perturbations by biological modifiers.

Entities:  

Mesh:

Year:  2003        PMID: 14555711

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  35 in total

Review 1.  Evolution of acquired resistance to anti-cancer therapy.

Authors:  Jasmine Foo; Franziska Michor
Journal:  J Theor Biol       Date:  2014-03-25       Impact factor: 2.691

2.  Population ecology of heterotypic tumour cell cultures.

Authors:  M Sega; R Chignola
Journal:  Cell Prolif       Date:  2014-08-27       Impact factor: 6.831

3.  An evolutionary hybrid cellular automaton model of solid tumour growth.

Authors:  P Gerlee; A R A Anderson
Journal:  J Theor Biol       Date:  2007-02-12       Impact factor: 2.691

4.  Edge effects in game-theoretic dynamics of spatially structured tumours.

Authors:  Artem Kaznatcheev; Jacob G Scott; David Basanta
Journal:  J R Soc Interface       Date:  2015-07-06       Impact factor: 4.118

5.  The prisoner's dilemma as a cancer model.

Authors:  Jeffrey West; Zaki Hasnain; Jeremy Mason; Paul K Newton
Journal:  Converg Sci Phys Oncol       Date:  2016-07-04

6.  Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.

Authors:  Aaron N Hata; Harald Paganetti; Clemens Grassberger; David McClatchy; Changran Geng; Sophia C Kamran; Florian Fintelmann; Yosef E Maruvka; Zofia Piotrowska; Henning Willers; Lecia V Sequist
Journal:  Cancer Res       Date:  2019-05-21       Impact factor: 12.701

7.  Biological factors, tumor growth kinetics, and survival after metastasectomy for pulmonary melanoma.

Authors:  Jonathan H Lee; Seza A Gulec; Ainura Kyshtoobayeva; Myung-Shin Sim; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2009-07-15       Impact factor: 5.344

8.  Evolution of cell motility in an individual-based model of tumour growth.

Authors:  P Gerlee; A R A Anderson
Journal:  J Theor Biol       Date:  2009-03-12       Impact factor: 2.691

Review 9.  Tumor heterogeneity: causes and consequences.

Authors:  Andriy Marusyk; Kornelia Polyak
Journal:  Biochim Biophys Acta       Date:  2009-11-18

Review 10.  Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma.

Authors:  José I López; Javier C Angulo
Journal:  Curr Urol Rep       Date:  2018-01-27       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.